[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Minicircle\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100609607",false,"NCT07216781","Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans","Evaluating the Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans: An Interventional, Non-Placebo-Controlled Pilot Phase Study","Inclusion Criteria:\n\n* Participant is open to morphological change\n* If female, participant agrees to maintain contraception\n* If female, participant agrees to take a pregnancy test\n* If female, participant agrees to a pregnancy waiver\n\nExclusion Criteria:\n\n* Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study\n* History of cancer diagnosis\n* Preexisting medical issues that may be exacerbated by the treatment\n* Has received any gene therapy within the past 12 months\n* Unwilling or unable to provide written informed consent",true,"ALL","23 Years","90 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to investigate the safety and efficacy of a gene therapy for Klotho, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of the Klotho gene therapy.",[27],"Healthy Adults",[29,30,31],"Klotho","plasmid","gene therapy","RECRUITING","2026-02-15",{"date":35,"type":36},"2026-02-17","ACTUAL",{"date":38,"type":36},"2025-10-06",{"date":40,"type":21},"2026-08",{"name":42,"class":43},"Minicircle","INDUSTRY",{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":15,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":5},"100614902","NCT07285629","Safety and Efficacy of Klotho and Follistatin Gene Therapy","Evaluating the Safety and Efficacy of Injectable Combination Klotho and Follistatin Plasmid Gene Therapy in Humans -- An Interventional, Non-Placebo Controlled Pilot Phase Study","Inclusion Criteria:\n\n* Adults aged 50 to 80 years\n* General good health\n* Willing to comply with all study-related procedures and visits\n* Participant is open to morphological change\n* If female, participant agrees to maintain contraception\n* If female, participant agrees to take a pregnancy test\n* If female, participant agrees to a pregnancy waiver\n\nExclusion Criteria:\n\n* Currently enrolled in another clinical trial\n* History of cancer, autoimmune disease, or chronic kidney\u002Fliver disease\n* Use of immunosuppressive therapy\n* Pregnant or breastfeeding\n* Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study.\n* Regular use of NMDA (N-methyl-D-aspartate) antagonists (i.e., memantine, ketamine, etc.)\n* Regular use of antiplatelet medications (i.e., aspirin)\n* Any medical or psychiatric condition that could interfere with participation or pose safety concerns\n* Unwilling or unable to provide informed consent","50 Years","80 Years",{"count":53,"type":21},30,[55],"EARLY_PHASE1","The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.",[27],[59,60,61,31,30],"klotho","follistatin","nonviral","2026-01-06",{"date":64,"type":36},"2026-01-08",{"date":66,"type":36},"2025-12-16",{"date":68,"type":21},"2026-06",{"name":42,"class":43},""]